Abeona therapeutics announces successful type b meeting with fda for pivotal phase 3 viital™ study of eb-101 in recessive dystrophic epidermolysis bullosa (rdeb)

Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction
ABEO Ratings Summary
ABEO Quant Ranking